These included: Expressive communication Personal and domestic daily living skills Interpersonal skills Play-leisure skills Coping social skills Other clinical improvements observed with B12 included improvements in: Sleep Gastrointestinal symptoms Hyperactivity Tantrums Nonverbal intellectual quotient Vision Eye contact Echolalia Stereotypy Anemia Nocturnal enuresis (bed wetting) Adverse events with B12 identified by meta-analysis included: Hyperactivity (11.9%) Irritability (3.4%) Trouble sleeping (7.6%) Aggression (1.8%) Worsening behaviors (7.7%) But adverse effects were generally few, mild, not serious, and not significantly different compared to placebo
Tested for purity and consistency
The first is extracellular matrix biology: fibroblast culture and rat wound-chamber work from the Maquart and Simeon groups reported that GHK-Cu stimulates collagen, glycosaminoglycan and small proteoglycan synthesis while simultaneously upregulating matrix metalloproteinase-2 and its tissue inhibitors, a combined synthesis-and-turnover signature unusual among matrix-active compounds
Patients should be counseled to watch for excessive drowsiness, impaired coordination, and respiratory depression (particularly if opioids are also in the regimen, since gabapentin is a known respiratory-risk amplifier when combined with opioids) [5]
Cagrilintide as a standalone medication is earlier in development, so an individual approval is likely further out, possibly 2028 or beyond